Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for NSCLC patients harboring activating EGFR mutations [3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.